MWNA
TCRT icon

Marshall Wace North America’s Alaunos Therapeutics TCRT Stock Holding History

Marshall Wace North America’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1.71M Buy
+6,265
New +$1.92M 0.01% 768
2018
Q3 		– Sell
-180
Closed -$82K – 1357
2018
Q2 		$82K Buy
+180
New +$114K ﹤0.01% 1324

Other funds holding TCRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MP
MSD Partners New York $76.8M AUM 34.91% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Marshall Wace North America's TCRT Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Alaunos Therapeutics (TCRT) in Q3 2021: 6,265 shares worth $1.71M. The stake represents 0.01% of the portfolio and ranks #768 among its holdings. This is a return to the name: Marshall Wace North America previously reported a position in TCRT as recently as Q2 2018.

Marshall Wace North America first reported a position in TCRT in Q2 2018 and has held it in 2 quarters since. 162 funds tracked by Wall St. Rank hold TCRT as of Q3 2021.

  • Marshall Wace North America held 6,265 shares of Alaunos Therapeutics worth $1.71M as of Q3 2021.
  • Alaunos Therapeutics was a new Marshall Wace North America position in Q3 2021.
  • Alaunos Therapeutics made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #768 holding.
  • Marshall Wace North America first reported a position in Alaunos Therapeutics in Q2 2018 and has held it in 2 quarters since.
  • 162 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.